THERAPY DOSSIER · th-74768382472f

Colchicine

Drug · Tubulin INHIBITOR; inhibits microtubule assembly by binding to beta tubulin (target CHEMBL2095182). ATC M04AC01.

No trauma translation Suggest a correction

This record is classified as “NO TRAUMA TRANSLATION”. Read the indication and notes below for the specific context.

Evidence & regulatory context

Mechanism: Tubulin INHIBITOR; inhibits microtubule assembly by binding to beta tubulin (target CHEMBL2095182). ATC M04AC01.
Target: CHEMBL2095182 (tubulin)
Injury models: Wound
Reported indication: Not recorded
First approval: 1961
Development stage: Not recorded
ChEMBL record: CHEMBL107 ↗
ChEMBL max phase: 4 / 4 (development scale, not regulatory approval)
Synonyms: Colchicine; Colcrys; Mitigare; Gloperba; Lodoco; Colchicinum; NSC-757
Note: Not recorded

Clinical trials 6

0 linked trials carry an injury-indication flag. These flags support record-level exploration and sit alongside the stringent aggregate counts described in Methods.

NCT05168137 ↗PHASE4unknown

Efficacy and Safety of Low-Dose Colchicine on Surrogate Markers of Cardiovascular Events in People Living With HIV Receiving Antiretroviral Therapy

HIV Infections · Inflammatory Markers · Colchicine Adverse Reaction

Enrolment: 84 · Results not recorded

NCT07247734 ↗PHASE2recruiting

The Effect of Colchicine on Insulin Sensitivity in Individuals With Type 1 Diabetes and Systemic Low-grade Inflammation

Type 1 Diabetes · Chronic Inflammation · Insulin Sensitivity

Enrolment: 26 · Results not recorded

NCT04355585 ↗PHASE1unknown

Revisiting the Mechanism of the Anti-inflammatory Effect of Colchicine

Colchicine Mechanism of Action

Enrolment: 18 · Results not recorded

NCT05118737 ↗EARLY_PHASE1unknown

Adding Colchicine to Tocilizumab in Hospitalized Patients With Severe COVID-19 Pneumonia

COVID-19 Pneumonia

Enrolment: 230 · Results not recorded

NCT01017042 ↗PHASE1completed

Open-Label Pharmacokinetic Study of a Low-Dose Acute Gout Regimen

Pharmacokinetics

Enrolment: 13 · Results not recorded

NCT05930002 ↗NAcompleted

Role of Ivermectin and Colchicine in Treatment of COVID-19

COVID-19

Enrolment: 120 · Results not recorded

Preclinical evidence 1

1 studies reported at therapy level; 1 evidence entries itemised.

PMID 29108466 ↗2017Mixed findings

Colchicine alleviates acute postoperative pain but delays wound repair in mice: roles of neutrophils and macrophages.

MouseWoundC57BL/6JMaleIntraperitoneal (colchicine); intravenous (clodronate liposomes)0.75 mg/kg in sterile saline; comparator clodronate liposom…Colchicine started 2 days before the incision; clodronate liposomes given 1 h b…

Model: Plantar incision model of postoperative pain: 5 mm longitudinal incision through skin and fascia of the right hind paw starting 2 mm from the heel, with elevation of the plantaris muscle and no suturing so wound repair could be assessed

Colchicine 0.75 mg/kg attenuated incision-induced mechanical hypersensitivity on day 1 and reduced Gr1-positive neutrophil infiltration at days 1 and 3 and Iba1 macrophage immunoreactivity at day 3, with lower IL1beta and CD86 mRNA. However it significantly delayed wound closure at day 3 and attenu…

Extraction: extract · Supplied extraction confidence: 0.9. Machine-extracted fields require source verification.

Loading the evidence…